dual antiplatelet therapy

Higher percentage of strut coverage in biodegradable polymer DES vs. durable polymer DES. Strut level OCT analyses

Original title:&nbsp;Randomized comparison of strut coverage between Nobori biolimus-eluting and sirolimus-eluting stents: an optical coherence tomography analysis.&nbsp;Reference: &nbsp;EuroIntervention 2014; 9-online publish-ahead-of-print February 2014 &nbsp; The aim of this study was to compare strut coverage at six months follow up after Nobori biolimus eluting stent (N- BES) implantation versus Cypher Select sirolimus eluting stent (SES) implantation.<a href="https://solaci.org/en/2014/05/27/n-4474/" title="Read more" >...</a>

Malapposition in drug-eluting stents. Much more common and much less serious than we thought

Original title:&nbsp;Incidences, Predictors, and Clinical Outcomes of Acute and Late Stent Malapposition Detected by Optical Coherence Tomography After Drug-Eluting Stent Implantation&nbsp;Reference:&nbsp;Im E. et al. CircCardiovascInterv. 2014 Jan 14. [Epubahead of print] &nbsp; This paper analyzed the imaging of 351 patients by optical coherence tomography (OCT) who received drug-eluting stents over 356 lesions between 2009 and<a href="https://solaci.org/en/2014/01/28/n-4187/" title="Read more" >...</a>

Looking for the best anti-aggregation scheme after TAVI

Original title:&nbsp;Comparison of Two Antiplatelet Therapy Strategies in Patients Undergoing Transcatheter Aortic Valve Implantation.&nbsp;Reference: Eric Durand et al. Am J Cardiol 2013, et al. Percutaneous aortic valve replacement has been shown to be superior to medical treatment in inoperable patients and not inferior to surgery in high-risk patients. Anti-platelet therapy in these patients is usually<a href="https://solaci.org/en/2013/11/08/n-4061/" title="Read more" >...</a>

Cilostazol reduces restenosis of DES in lesions larger than 40 mm.

Original title:&nbsp;Comparison of Dual Versus Triple Antiplatelet Therapy After Drug-Eluting Stent According to Stent Length (from the Pooled Analysis of DECLARE Trials).&nbsp;Reference:&nbsp;Seung-Whan Lee et al. Am J Cardiol 2013, article in press. Cilostazol, an inhibitor of phosphodiesterase III , associated with aspirin and clopidogrel showed decrease angiographic restenosis both in conventional stents as well as<a href="https://solaci.org/en/2013/10/07/n-3697/" title="Read more" >...</a>

Stent Thrombosis in the Real World 

Original title:&nbsp;Incidence and predictors of stent trombosis: a single-centre study of 5833 consecutive patients undergoing coronary artery stenting&nbsp;Reference:&nbsp;Javaid Iqbal et al. EuroInterventional 2013;9:62-69 Though potentially fatal, stent thrombosis is a low frequency event associated to stent malapposition, fractures, resistance to antiplatelet therapies, and diseases such as diabetes and kidney disease, among other factors. 5883 pacients<a href="https://solaci.org/en/2013/05/31/n-2773/" title="Read more" >...</a>

Prasugrel is not as effective as Ticagrelor in acute myocardial infarction. 

Original title:&nbsp;Comparison of Prasugrel and Ticagrelor loading doses in STEMI patients: The Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI Study.&nbsp;Reference:&nbsp;Guido Parodi et al. J Am Coll Cardiol 2013. Article in press. Current guidelines recommend the use of prasugrel or ticagrelor in patients with ST elevation acute coronary syndromes who are due to receive<a href="https://solaci.org/en/2013/04/01/n-2787/" title="Read more" >...</a>

A new paradigm in the treatment of in-stent restenosis?

Original title:&nbsp;ISAR DESIRE 3: Drug-eluting balloon is best option for restenosis of limus-eluting stents&nbsp;Reference:&nbsp;Dr Robert Byrne. TCT 2012. Miami, Fl. The first of the ISAR DESIRE trials showed that drug-eluting stents (DES) were the best strategy for treating restenosis of a bare metal stent, the second ISAR DESIRE trial tested the hypothesis of changing or<a href="https://solaci.org/en/2012/11/11/n-3746/" title="Read more" >...</a>

In patients with stroke history, Ticagrelor is superior to Clopidogrel

James SK, Storey RF, Khurmi N, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack. Circulation 2012. A sub-analysis of the PLATO study demonstrated similar superiority and the safety of ticagrelor in all patients, regardless of any previous history of stroke. Ticagrelor versus clopidogrel:<a href="https://solaci.org/en/2012/09/01/n-3984/" title="Read more" >...</a>

Top